In recent studies, the epigenetic regulation of the PD‐1/PD‐L1 pathway has emerged as a potential predictor of immunotherapy response in various malignancies, including NSCLC, melanoma, and GC.87, 88, 89, 90. Here, CD274 is linked to melanoma.